In the long arc of healthcare investing, moments of fear-driven selling sometimes obscure the underlying strength of businesses built to endure. Abbott Laboratories finds itself at such a crossroads in mid-2026, its shares depressed enough that at least one analyst sees not a broken company but a mispriced one — a diversified manufacturer with cancer diagnostics ambitions, a reliable dividend, and a gap between perception and fundamental value that patient capital might one day close.